Evidence map›Paper›PMID 41711202›Full record

Trial reportESC heart failure2026

Phase 2b trial of an oral relaxin family peptide receptor 1 agonist in patients with chronic heart failure: rationale and design.

Macarena P Quintana-Hayashi, Kathleen Connolly, Marcus Millegård, Chandrali Bhattacharya, Magnus Åstrand, Michelle Turton, Patricia Ely Pizzato, James L Januzzi, Jaya B Rosenmeier

Abstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Macarena P Quintana-HayashiEarly Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Kathleen ConnollyEarly Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Marcus MillegårdBiometrics, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Chandrali BhattacharyaClinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Magnus ÅstrandClinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Michelle TurtonBioPharmaceuticals Clinical Operations, R&D, AstraZeneca, Cambridge, UK.
Patricia Ely PizzatoEarly Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
James L JanuzziBaim Institute for Clinical Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jaya B RosenmeierEarly Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.ORCID 0009-0004-2401-0235

Funding

AstraZeneca
6 · The paper itself

Abstract

introductionAZD5462 is the first oral relaxin family peptide receptor 1 agonist in clinical development and is expected to reduce systemic vascular resistance and afterload and to increase natriuresis, decreasing circulating blood volume, benefitting patients with chronic heart failure (HF). LUMINARA is a Phase 2b study of the efficacy and safety of AZD5462 in participants with broad HF. STUDY

designThis randomized, placebo-controlled, double-blind, multi-centre, dose-ranging study will include ∼360 participants with HF: 220 with left ventricular ejection fraction (LVEF) ≤35% (Cohort A) and 140 with LVEF 41%-55% (Cohort B) will be randomized 1:1:1:1 to three once daily oral doses of AZD5462 or placebo for 24 weeks. Primary endpoints are changes in end-systolic volume index (Cohort A) and systemic vascular resistance index (Cohort B) after 24 weeks. Secondary endpoints include changes in echocardiographic parameters, health status, cardiorenal biomarkers and pharmacokinetics. The safety of AZD5462 will be monitored throughout the study. DISCUSSION: This study will evaluate AZD5462 as a novel oral therapy for patients with chronic HF, aiming to improve symptoms as well as haemodynamic and cardiorenal biomarkers. The findings may provide insights on the development of AZD5462 in a future Phase 3 trial.

Indexed as

Heart FailureReceptors, PeptideStroke VolumeVentricular Function, LeftAdministration, OralChronic DiseaseDose-Response Relationship, DrugDouble-Blind MethodEchocardiographyFemaleFollow-Up StudiesHumansMaleMiddle AgedRelaxinTreatment OutcomeReceptors, PeptideRelaxinEnd-systolic volume index (ESVI)Heart failurePhase 2 trialRelaxinRXFP1 agonistSystemic vascular resistance index (SVRI)

Identifiers

PMID41711202
PMCPMC13232748

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.